| pubmed-article:2471587 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0108747 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0205160 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C1367475 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C1752435 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:2471587 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:2471587 | pubmed:issue | 13 | lld:pubmed |
| pubmed-article:2471587 | pubmed:dateCreated | 1989-7-27 | lld:pubmed |
| pubmed-article:2471587 | pubmed:abstractText | The phenotype and function of lymphocytes from cancer patients treated with repetitive weekly cycles of continuous i.v. infusions of recombinant interleukin 2 (IL-2) were examined. Peripheral blood lymphocytes (PBL) obtained after IL-2 therapy showed an increased percentage of cells bearing the CD16 and leu19 markers which are associated with natural killer cells. These PBL mediated significantly increased levels of IL-2-dependent lymphokine-activated killer (LAK) activity against the Daudi cell line. Depletion of CD16+ cells from PBL obtained after in vivo IL-2 caused only slight inhibition of their LAK activity or their proliferative response to IL-2 in vitro. This indicates that CD16+ cells are involved but play only a minor role in these responses. In contrast, depletion of leu19+ cells, from PBL activated in vivo with IL-2, virtually abrogated their LAK activity and their proliferative response to IL-2. Two-color flow cytometry studies showed that a leu19+/CD16- population was expanded by in vivo IL-2 therapy and was responsible for the majority of LAK activity by in vivo-activated PBL. Moreover, this CD16- population showed an increased density of leu19 and CD2 (E rosette receptor) antigens when compared to the resting PBL obtained prior to IL-2 treatment. These data show that the predominant population mediating in vitro LAK activity, induced by in vivo IL-2 therapy, consists of activated natural killer cells with a high density of leu19 and CD2 antigens but negative for the CD16 antigen. | lld:pubmed |
| pubmed-article:2471587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2471587 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2471587 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2471587 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:2471587 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:2471587 | pubmed:author | pubmed-author:SondelP MPM | lld:pubmed |
| pubmed-article:2471587 | pubmed:author | pubmed-author:HandJ HJH | lld:pubmed |
| pubmed-article:2471587 | pubmed:author | pubmed-author:SosmanJ AJA | lld:pubmed |
| pubmed-article:2471587 | pubmed:author | pubmed-author:FischPP | lld:pubmed |
| pubmed-article:2471587 | pubmed:author | pubmed-author:Weil-HillmanG... | lld:pubmed |
| pubmed-article:2471587 | pubmed:author | pubmed-author:PrieveA FAF | lld:pubmed |
| pubmed-article:2471587 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2471587 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:2471587 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:2471587 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2471587 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2471587 | pubmed:pagination | 3680-8 | lld:pubmed |
| pubmed-article:2471587 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:meshHeading | pubmed-meshheading:2471587-... | lld:pubmed |
| pubmed-article:2471587 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2471587 | pubmed:articleTitle | Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. | lld:pubmed |
| pubmed-article:2471587 | pubmed:affiliation | Department of Human Oncology, University of Wisconsin, Madison. | lld:pubmed |
| pubmed-article:2471587 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2471587 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:2471587 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2471587 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2471587 | lld:pubmed |
